Breakthrough in the Treatment Of Hepatitis C: FDA Approves Two New Drugs

In May, the FDA approved the drugs boceprevir (Victrelis) and telaprevir (Incivek) in the fight to treat Hepatitis C, affecting over 4 million Americans. FDA director, Dr. Edward Cox, said in a statement. "The availability of new therapies that significantly increase responses while potentially decreasing the overall duration of treatment is a major step forward in the battle against chronic hepatitis C infection."